A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis | Neurology
Meet the Compound: Laquinimod – HD Insights
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Laquinimod - an overview | ScienceDirect Topics
laquinimod
Cells | Free Full-Text | Laquinimod Supports Remyelination in Non-Supportive Environments
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Multiple Sclerosis Research: Will Teva and Biogen Come together for the sake of DMF, laquinimod polypill
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
FDA Marks Change in Clinical Test Dose of MS Therapy, Laquinimod
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
AhR activators - friend or foe? - Hypha Discovery Blogs
AhR activators - friend or foe? - Hypha Discovery Blogs
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Laquinimod - an overview | ScienceDirect Topics
Laquinimod | C19H17ClN2O3 | CID 54677946 - PubChem
Laquinimod sodium (ABR-215062 sodium) | Immunomodulator | MedChemExpress
Molecules | Free Full-Text | Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS | Fierce Pharma
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
A Broad Look At Teva's Pipeline (NYSE:TEVA) | Seeking Alpha
Teva hit with largest-ever fine under US anti-corruption act - PMLiVE
Laquinimod - an overview | ScienceDirect Topics
